BridgeBio Pharma, Inc.
NASDAQBridgeBio Pharma heads into its October 30 earnings print with a well-entrenched short position, a shrinking activist register, and a Street that remains broadly constructive despite a 10% pullback over the past month. Short interest is the clearest structural fact about this stock right now. At 11.3% of the free float, the short position has been remarkably stable, barely moving…
BBIO put/call ratio surges to 1.24, four standard deviations above its 20-day mean of 0.26, signaling heavy pre-earnings hedging ahead of July 31 earnings print.
BridgeBio Pharma heads into its October 30 earnings print with a well-entrenched short position, a shrinking activist register, and a Street that remains broadly constructive despite a 10% pullback over the past…
BridgeBio Pharma enters the final week of September with a curious split: the stock has given back 15% over the past month yet recovered nearly 4% on Tuesday, while two of its largest activist investors have been…
Snapshot as of 10 Oct 2026
BridgeBio Pharma enters September with the options panic from last week fully unwound, yet the underlying short position is quietly growing again — a tension worth watching as the stock slides toward its next earnings…
BridgeBio Pharma heads into the back half of August with an unusual tension: the options market just fired its most defensive signal in months, even as every major analyst on the Street raised their price target two…
BridgeBio Pharma has flipped its positioning story in 48 hours — shorts are covering at pace, analysts are lifting targets in unison, and the options tape has swung from extreme bullishness to a defensive pulse that…
BBIO enters its August 10 earnings report with options traders firmly positioned for upside — a notable contrast to the elevated short interest that has built steadily over the past month. The clearest signal heading…
BridgeBio Pharma heads into its July 31 earnings print with one of the sharpest options sentiment reversals in the past year — even as the stock has climbed 24% in a month. The options market is flashing a warning that…
BridgeBio Pharma heads into the final stretch of Q2 with its strongest monthly gain in recent memory — but one corner of the market is turning sharply defensive just as the tape improves. The stock closed at $74.48 on…
BridgeBio Pharma heads into its June 22 earnings date with a notable split: the options market has swung back to bullish extremes, the lending pool is flush, and fresh analyst initiations are clustering above current…
BridgeBio Pharma enters the final stretch before its June 22 earnings with a cluster of insider sales at the top, a dramatic single-day shift in options sentiment, and a short position that — while elevated — has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BBIO — free to start on ORTEX.
Sign up for free →Open BBIO on ORTEX